Breakthrough drug helps rare obesity condition, but other research uncertain amid cuts
Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds the cupboard was left unlocked. They rushed to the emergency room, fearing a dangerous bowel impaction.
The irony stung: When Dean was born, he was so weak and floppy he survived only with feeding tubes because he couldn't suck or swallow. He was diagnosed as a baby with Prader-Willi syndrome — a rare disorder sparked by a genetic abnormality. He continued to be disinterested in food for years. But doctors warned that as Dean grew, his hunger would eventually become so uncontrollable he could gain dangerous amounts of weight and even eat until his stomach ruptured.
"It's crazy," said Foley Shenk, who lives in Richmond, Virginia. "All of a sudden, they flip."
Prader-Willi syndrome affects up to 20,000 people in the U.S. The most striking symptom is its most life-threatening: an insatiable hunger known as hyperphagia that prompts caregivers to padlock cupboards and fridges, chain garbage cans, and install cameras. Until recently, the only treatment was growth hormone therapy to help patients stay leaner and grow taller, but it didn't address appetite.
In March, the Food and Drug Administration approved Vykat XR, an extended-release version of the existing drug diazoxide choline, which eases the relentless hunger and may offer insights into the biology of extreme appetite and binge eating. This breakthrough for these patients comes as other drugs are revolutionizing how doctors treat obesity, which affects more than 40% of American adults. GLP-1 agonist medications Ozempic, Wegovy, and others also are delivering dramatic results for millions.
But what's becoming clear is that obesity isn't one disease — it's many, said Jack Yanovski, a senior obesity researcher at the National Institutes of Health, who co-authored some of the Vykat XR studies. Researchers are learning that obesity's drivers can be environmental, familial, or genetic. "It only makes sense that it's complex to treat," Yanovski said.
Obesity medicine is likely heading the way of treatments for high blood pressure or diabetes, with three to five effective options for different types of patients. For example, up to 15% of patients in the GLP-1 trials didn't respond to those drugs, and at least one study found the medications didn't significantly help Prader-Willi patients.
Yet, researchers say, efforts to understand how to treat obesity's many causes and pathways are now in question as the Trump administration is dismantling the nation's infrastructure for medical discovery.
While Health and Human Services Secretary Robert F. Kennedy Jr. promotes a "Make America Healthy Again" agenda centered on diet and lifestyle, federal funding for health research is being slashed, including some grants that support the study of obesity. University labs face cuts, FDA staffers are being laid off en masse, and rare disease researchers fear the ripple effects across all medical advances. Even with biotech partnerships — such as the work that led to Vykat XR — progress depends on NIH-funded labs and university researchers.
"That whole thing is likely to get disrupted now," said Theresa Strong, research director for the Foundation for Prader-Willi Research.
HHS spokesperson Andrew Nixon said in a statement that no NIH awards for Prader-Willi syndrome research have been cut. "We remain committed to supporting critical research into rare diseases and genetic conditions," he said.
But Strong said that already some of the contacts at the FDA she'd spent nearly 15 years educating about the disorder have left the agency. She's heard that some research groups are considering moving their labs to Europe.
Early progress in hunger and obesity research is transforming the life of Dean Shenk. During the trial for Vykat XR, his anxiety about food eased so much that his parents began leaving cupboards unlocked.
Jennifer Miller, a pediatric endocrinologist at the University of Florida who co-led the Vykat XR trials, treats around 600 Prader-Willi patients, including Dean. She said the impact she's seen is life-changing. Since the drug trial started in 2018, some of her adult patients have begun living independently, getting into college, and starting jobs — milestones that once felt impossible. "It opens up their world in so many ways."
Over 26 years in practice, she's also seen just how severely the disease hurts patients. One patient ate a four-pound bag of dehydrated potato flakes; another ingested all 10 frozen pizzas from a Costco pack; some ate pet food. Others have climbed out of windows, dived into dumpsters, even died after being hit by a car while running away from home in search of food.
Low muscle tone, developmental delays, cognitive disabilities, and behavioral challenges are also common features of the disorder.
Dean attends a special education program, his mother said. He also has narcolepsy and cataplexy — a sudden loss of muscle control triggered by strong emotions. His once-regular meltdowns and skin-picking, which led to deep, infected lesions, were tied to anxiety over his obsessive, almost painful urge to eat.
In the trial, though, his hyperphagia was under control, according to Miller and Dean's mother. His lean muscle mass quadrupled, his body fat went down, and his bone mineral density increased. Even the skin-picking stopped, Foley Shenk said.
Ali Foley Shenk (right) and her son Dean, at their home in Richmond, Virginia. Dean was born with Prader-Willi syndrome — a rare disorder that causes hyperphagia, a medical term for insatiable hunger. Since starting on a new medication as part of a clinical trial, his symptoms have improved, his mother says.
Parker Michels-Boyce for KFF Health News
Vykat XR is not a cure for the disease. Instead, it calms overactive neurons in the hypothalamus that release neuropeptide Y — one of the body's strongest hunger signals. "In most people, if you stop secreting NPY, hunger goes away," said Anish Bhatnagar, CEO of Soleno Therapeutics, which makes the medication, the company's first drug. "In Prader-Willi, that off switch doesn't exist. It's literally your brain telling you, 'You're starving,' as you eat."
GLP-1 drugs, by contrast, mimic a gut hormone that helps people feel full by slowing digestion and signaling satiety to the brain.
Vykat XR's possible side effects include high blood sugar, increased hair growth, and fluid retention or swelling, but those are trade-offs that many patients are willing to make to get some relief from the most devastating symptom of the condition.
Still, the drug's average price of $466,200 a year is staggering even for rare-disease treatments. Soleno said in a statement it expects broad coverage from both private and public insurers and that the copayments will be "minimal." Until more insurers start reimbursing the cost, the company is providing the drug free of charge to trial participants.
Soleno's stock soared 40% after the FDA nod and has held fairly steady since, with the company valued at nearly $4 billion as of early June.
While Vykat XR may be limited in whom it can help with appetite control, obesity researchers are hoping the research behind it may help them decode the complexity of hunger and identify other treatment options.
"Understanding how more targeted therapies work in rare genetic obesity helps us better understand the brain pathways behind appetite," said Jesse Richards, an internal medicine physician and the director of obesity medicine at the University of Oklahoma-Tulsa's School of Community Medicine.
That future may already be taking shape. For Prader-Willi, two other notable phase 3 clinical trials are underway, led by Acadia Pharmaceuticals and Aardvark Therapeutics, each targeting different pathways. Meanwhile, hundreds of trials for general obesity are currently recruiting despite the uncertainties in U.S. medical research funding.
That brings more hope to patients like Dean. Nearly six years after starting treatment, the now-16-year-old is a calmer, happier kid, his mom said. He's more social, has friends, and can focus better in school. With the impulse to overeat no longer dominating his every thought, he has space for other interests — Star Wars, American Ninja Warrior, and a healthy appreciation for avocados among them.
"Before the drug, it just felt like a dead end. My child was miserable," Foley Shenk said. "Now, we have our son back."
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
The Best Late-Night Snack to Lower Cholesterol, According to Dietitians
Reviewed by Dietitian Karen Ansel, M.S., RDNMillions of Americans have high cholesterol, which can lead to heart disease. A bedtime snack rich in fiber and plant protein may help lower cholesterol. For a cholesterol-lowering late-night snack, our Chia Seed Pudding checks all the you have high cholesterol, you're not alone. According to the Centers for Disease Control and Prevention, millions of Americans have high cholesterol (aka hyperlipidemia). This condition, defined as total blood cholesterol levels higher than 200 mg/dL, is a leading risk factor for heart disease. However, that doesn't mean you're destined for heart troubles. 'Keeping cholesterol levels in a healthy range helps reduce the risk of plaque buildup in the arteries, which can lead to heart disease over time,' says Kathleen Benson, RDN, CSSD, CPT. Of course, healthy meals are the foundation of a cholesterol-lowering diet. But snacks can help, too—even the ones you eat before bed, like our Chia Seed Pudding. It's loaded with ingredients that can help reduce cholesterol. Yet, it's light and satisfying enough that it won't mess with your sleep. No wonder dietitians are huge fans. Here's how it can help keep your heart healthy. One of the myriad benefits of enjoying a high-fiber diet is that it can help lower cholesterol levels. 'When I have a client trying to manage high cholesterol levels, we focus on getting more fiber and healthier fats in their diet,' says Meggie Connelly, M.S., RD, LDN. Filled with fiber-rich chia seeds, our Chia Seed Pudding delivers a hefty 11 grams of fiber per serving. Chia seeds contain a mix of both soluble and insoluble fiber. But it's their soluble fiber that's behind chia's cholesterol-lowering powers. The reason? Soluble fiber can absorb some of the cholesterol in your gut, removing it from the body before it can cause trouble. Interestingly, research has shown that cholesterol from food doesn't always affect your blood cholesterol levels. The real culprit is saturated fat, found mainly in full-fat dairy, red and processed meat, lard and ghee. Saturated fat tells your liver to rev up its cholesterol production, which provides far more cholesterol than the amount we absorb from food. Since this chia pudding is made with almond milk, it contains merely 1 gram of saturated fat per serving. If almond milk isn't your thing, feel free to sub in another plant-based milk like soy, cashew or oat milk or low-fat cow's milk. Just steer clear of coconut milk and full-fat cow's milk, which are both high in saturated fat. Whether you have high cholesterol or not, choosing a late-night snack that contains some protein is the key to staying satiated all night long. 'This will help you feel full during the night and help control blood sugar levels so you're not starving by the morning,' says Brannon Blount, M.S., RDN. Each serving of this chia pudding delivers 7 grams of protein. And not just any kind of protein. All of its protein is plant protein, which has been linked to better heart health. It's so beneficial that the American Heart Association recommends getting most of our protein from plant sources like the chia seeds and nuts in this recipe. A combination of fiber and protein. Consider this the magic duo. 'Fiber and protein combined, or paired together with an assortment of foods, can support steady blood sugar and satiety,' Benson says. That's important because chronically high blood sugar levels can lead to diabetes, which increases heart disease risk. Ingredients that are easy to digest. When you're trying to get some quality zzz's, the last thing you need to eat is something that will upset your tummy or delay sleep even further. Choose something light, easy to digest and satisfying, yet low in fat and added sugars. In addition to chia pudding, oatmeal, popcorn and cereal with low-fat milk are all great options. Something simple to assemble. After a long day, it's normal to experience some decision fatigue. But, instead of reaching for something with empty calories (we're looking at you, bag of chips), choose something nutrient-dense that you can easily whip up. 'Your late-night snack needs to be quick and easy to put together, like a banana and nut butter, or a peanut butter and sliced strawberry sandwich on whole-grain bread. Or make your chia pudding in advance,' says Connelly. 'If you have to spend 30 minutes making your late-night snack, it's not going to be something you do consistently.' Late-night snacking may get a bad rap, but if you didn't eat enough during the day, a little nibble before bed might help you fall and stay asleep. That said, if you have high cholesterol, there are some considerations to keep in mind. If cholesterol is an issue, dietitians recommend choosing a snack that's rich in fiber, low in saturated fat and contains some protein. Our Chia Seed Pudding checks all the boxes. So, whip some up today. You can double (or even quadruple) the recipe. And it will stay fresh in your fridge for up to three days for a hassle-free bedtime snack your heart will thank you for. Read the original article on EATINGWELL
CBS News
an hour ago
- CBS News
Allegheny County issues code red heat advisory due to impending heat wave
Allegheny County will activate a code red heat advisory beginning Sunday, June 22, through Wednesday, June 25, due to extreme forecasted heat that could pose risks to vulnerable residents. The activation is based on the National Weather Service and Centers for Disease Control's HeatRisk tool, which considers how unusual and prolonged the heat is for this time of year, as well as the potential for serious health impacts, according to a provided news release from county officials. "We've always responded to heat emergencies, but this year we're being more systematic," said Erin Dalton, Director of the Allegheny County Department of Human Services. "Senior centers will now more consistently extend their hours on Code Red days, and we'll be assessing conditions to potentially expand overnight shelter when extreme heat persists into the night. This pilot approach will help us learn what works best to keep people safe." Residents are encouraged to check on neighbors, friends, and family, especially those who are older or medically vulnerable. Allegheny County Emergency Services is reminding residents that heat is the leading weather-related cause of death nationwide, surpassing the fatalities caused by floods, tornadoes, hurricanes, and lightning. Tips to keep yourself safe during extreme heat include drinking plenty of water to stay hydrated, even if you are not thirsty; keeping cool by using wet towels, putting feet in cool water, and taking cool showers; spend as much time as possible in cool or air-conditioned buildings; staying out of the sun during the hottest part of the day; wear sunscreen and hats with other loose-fitting clothing; and never leave pets or children in vehicles. Cooling centers opening In response to the forecasted temperatures, CitiParks will open six cooling centers on Sunday, June 22, through Wednesday, June 25. When operating as a cooling center, senior centers will welcome residents of any age. The Department of Human Services is also taking additional actions, including outreach to older adults, children, and people experiencing homelessness, in coordination with the City of Pittsburgh and other municipalities, according to a news release. On Sunday, cooling centers will be open from 12 p.m. to 6 p.m. From Monday through Wednesday, the centers will operate from 8 a.m. to 7 p.m. A full list of operational cooling centers is below. Beechview Healthy Active Living Community Center 1555 Broadway Avenue Pittsburgh, Pa. 15216 Brighton Heights Healthy Active Living Community Center 3515 McClure Avenue Pittsburgh, Pa. 15212 Greenfield Healthy Active Living Community Center 745 Greenfield Avenue Pittsburgh, Pa. 15217 Homewood Healthy Active Living Community Center 7321 Frankstown Road Pittsburgh, Pa. 15208 Sheraden Healthy Active Living Community Center 720 Sherwood Avenue Pittsburgh, Pa. 15204 South Side Healthy Active Living Community Center 12th and Bingham Streets Pittsburgh, Pa. 15203
Business Insider
an hour ago
- Business Insider
Incyte announces FDA extends review period for Opzelura sNDA
The company states: 'Incyte (INCY) announced that the FDA has extended the review period for the supplemental New Drug Application, sNDA, for ruxolitinib cream, Opzelura, a topical Janus kinase inhibitor, for the treatment of children 2-11 years old with mild to moderate atopic dermatitis. The PDUFA action date has been extended by three months to September 19, 2025. The FDA extended the PDUFA action date to allow time to review additional chemistry, manufacturing and controls data on the 0.75% strength submitted by Incyte in response to a recent FDA information request.' Steven Stein, M.D., Chief Medical Officer, Incyte stated: 'We are confident in the potential of ruxolitinib cream to become an important non-steroidal, topical treatment option for pediatric patients with atopic dermatitis and we will continue to work closely with the FDA to ensure the Agency has all of the information needed to complete its review.' Confident Investing Starts Here:
